<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01448499</url>
  </required_header>
  <id_info>
    <org_study_id>GMCH-014-11</org_study_id>
    <nct_id>NCT01448499</nct_id>
  </id_info>
  <brief_title>Clozapine Versus Amisulpride in Treatment-resistant Schizophrenia Patients</brief_title>
  <acronym>ClozAmi</acronym>
  <official_title>Clozapine Versus Amisulpride Versus Their Combination in the Treatment of Drug-resistant Schizophrenia Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Geha Mental Health Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Geha Mental Health Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: schizophrenia is a debilitating mental disorder affecting about 1% of the general&#xD;
      population. About 30% of patients will not react to current drug treatment and defined as&#xD;
      treatment-resistant schizophrenia patients (TRSP). The best studied therapeutic option for&#xD;
      this population is clozapine therapy. Clozapine was shown to be effective than any other&#xD;
      antipsychotic drug in TRSP. Moreover, augmentation of clozapine was not demonstrated to be&#xD;
      more effective than clozapine monotherapy. Albeit Clozapine superiority in TRSP, its use may&#xD;
      be involved with many adverse effects, some of them are life-threatening, and need for&#xD;
      routine blood tests. Amisulpride is an atypical antipsychotic drug with a different mechanism&#xD;
      of action than clozapine, with less adverse effects. No study compared directly amisulpride&#xD;
      and clozapine in TRSP.&#xD;
&#xD;
      Study objective: to compare, for the first time, the broad clinical effectiveness of&#xD;
      clozapine and amisulpride and their combination in TRSP.&#xD;
&#xD;
      Study Design: a clinical, prospective, naturalistic, randomized, comparative study simulating&#xD;
      a real-world approach of clinical decision making.&#xD;
&#xD;
      Methods: a total of 140 TRSP will be recruited from a large regional mental health center.&#xD;
      Participants will be randomized into two treatment groups (70 in each group): clozapine&#xD;
      monotherapy and amisulpride monotherapy. Assessment will be done following 10 and 20 weeks of&#xD;
      treatment. In case of treatment failure (insufficient clinical response or severe adverse&#xD;
      effect) participants will be offered either to switch to clozapine treatment (for failed&#xD;
      amisulpride treatment) or to augment clozapine with amisulpride (for failed clozapine&#xD;
      monotherapy patients). Thereafter, participants will be followed-up for a year. Assessment&#xD;
      will be made using clinician rated scales and self-completed questionnaires, rating the broad&#xD;
      phenomenology of schizophrenia (psychosis, mood, anxiety, obsessive-compulsive, cognitive and&#xD;
      quality of life) and drug-related adverse effects (objective and subjective).&#xD;
&#xD;
      Analysis: comparison of the effectiveness of the three treatment groups: amisulpride,&#xD;
      clozapine and their combination, in the various dimensions of TRSP.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Withdrawn</overall_status>
  <start_date>October 2011</start_date>
  <primary_completion_date type="Anticipated">October 2013</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in Positive and Negative Syndrome Scale (PANSS)</measure>
    <time_frame>10, 20 weeks and endpoint</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clinical Global Impression - Severity (CGI-S)</measure>
    <time_frame>10 , 20 weeks and endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Beck Depression Inventory (BDI)</measure>
    <time_frame>10 , 20 weeks and endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Beck Anxiety Inventory (BAI)</measure>
    <time_frame>10, 20 weeks and endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Schizophrenia Quality of Life Scale (SQLS)</measure>
    <time_frame>10, 20 weeks and endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Simpson-Angus Scale (SAS)</measure>
    <time_frame>5, 10, 15, 20 weeks, endpoint</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in Clozapine Adverse Effects Inventory (CAEI)</measure>
    <time_frame>5, 10 ,15, 20 weeks, endpoint</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">0</enrollment>
  <condition>Schizophrenia</condition>
  <condition>Treatment Resistant Disorders</condition>
  <arm_group>
    <arm_group_label>Clozapine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Clozapine monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amisulpride</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Amisulpride monotherapy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Augmentation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Augmentation of clozapine with amisulpride</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine</intervention_name>
    <description>escalating dose of clozapine up to 900 mg/day</description>
    <arm_group_label>Clozapine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amisulpride</intervention_name>
    <description>escalating dose of amisulpride up to 800 mg/day</description>
    <arm_group_label>Amisulpride</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clozapine+Amisulpride</intervention_name>
    <description>augmentation of clozapine with amisulpride</description>
    <arm_group_label>Augmentation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Confirmed diagnosis of schizophrenia according to DSM-IV-TR criteria&#xD;
&#xD;
          2. Treatment-resistant schizophrenia, defined as: documented treatment failure&#xD;
             (insufficient clinical response or severe adverse effects) of two antipsychotics (one&#xD;
             of them should be atypical) for an adequate duration of 6 weeks and in a sufficient&#xD;
             dose of at least 600 mg/day of chlorpromazine equivalent&#xD;
&#xD;
          3. Age 18-65 years&#xD;
&#xD;
          4. Basal PANSS &gt; 75&#xD;
&#xD;
          5. CGI-S &gt;3&#xD;
&#xD;
          6. Persistent positive psychotic symptoms, with rating scores of moderate or worse on at&#xD;
             least two of four positive symptom items (delusions, conceptual disorganization,&#xD;
             hallucinatory behavior, and suspiciousness/persecution) on Positive and Negative&#xD;
             Syndrome Scale (PANSS).&#xD;
&#xD;
          7. Competent and willing to provide written, informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with concomitant treatment with lithium, anticonvulsants, antidepressants&#xD;
&#xD;
          2. Patients with underlying severe medical illness, such as cardiovascular disease,&#xD;
             cerebrovascular disease, bone marrow suppression or epilepsy&#xD;
&#xD;
          3. A previous trial of clozapine or amisulpride&#xD;
&#xD;
          4. Any known contraindication for treatment with clozapine or amisulpride&#xD;
&#xD;
          5. Any woman who is pregnant or planning a pregnancy, and any woman of child bearing&#xD;
             potential unless using adequate contraception&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Geha Mental Health Center</name>
      <address>
        <city>Petach-Tikva</city>
        <zip>49000</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <study_first_submitted>October 2, 2011</study_first_submitted>
  <study_first_submitted_qc>October 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 7, 2011</study_first_posted>
  <last_update_submitted>December 8, 2015</last_update_submitted>
  <last_update_submitted_qc>December 8, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 9, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Geha Mental Health Center</investigator_affiliation>
    <investigator_full_name>Amir Krivoy</investigator_full_name>
    <investigator_title>Senior psychiatrist</investigator_title>
  </responsible_party>
  <keyword>schizophrenia</keyword>
  <keyword>clozapine</keyword>
  <keyword>amisulpride</keyword>
  <keyword>combination</keyword>
  <keyword>treatment resistant</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Clozapine</mesh_term>
    <mesh_term>Amisulpride</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

